---
schema_version: '1.0'
id: government-20261021-b5dcbf
title: Regulatory Considerations for Prescription Drug Use-Related Software; Guidance
  for Industry; Availability
content_kind: government-document
url: https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry
url_hash: b5dcbfcdda81e7a7a17491052fadb2a1a17768d8ddeb7ec064b108db5d7a1d96
canonical_url: https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry
source: us-federal-register
category: government/us
category_raw: Notice
country: us
region: us
tags: []
lang: en
published_at: '2026-10-21T00:00:00Z'
fetched_at: '2026-10-21T09:01:23.417136Z'
updated_at: '2026-10-21T10:10:47Z'
status: published
content_hash: c740116bb1b738048790117196663dbfc18d183bffa4397752c68a5efd308db6
content_changed_at: null
license_note: full
license_basis: public-domain-17usc105
body_available: false
attribution: 'Source: Office of the Federal Register, National Archives and Records
  Administration'
license_rule: source:us-federal-register
summary: The Food and Drug Administration (FDA or Agency) is announcing the availability
  of a final guidance for industry titled "Regulatory Considerations for Prescription
  Drug Use-Related Software." This final guidance describes FDA's application of its
  drug labeling authorities to certain software outputs that are disseminated by or
  on behalf of a drug sponsor for use with a prescription drug product or a prescription
  drug-led, drug-device combination product that is assigned to the Center for Drug
  Evaluation and Research or the Center for Biologics Evaluation and Research as the
  lead center. This guidance finalizes the draft guidance of the same title issued
  on September 19, 2023.
summary_source: official
summary_en: The Food and Drug Administration (FDA or Agency) is announcing the availability
  of a final guidance for industry titled "Regulatory Considerations for Prescription
  Drug Use-Related Software." This final guidance describes FDA's application of its
  drug labeling authorities to certain software outputs that are disseminated by or
  on behalf of a drug sponsor for use with a prescription drug product or a prescription
  drug-led, drug-device combination product that is assigned to the Center for Drug
  Evaluation and Research or the Center for Biologics Evaluation and Research as the
  lead center. This guidance finalizes the draft guidance of the same title issued
  on September 19, 2023.
summary_omitted_reason: null
redistribution: true
keywords_en:
- Availability
- Considerations
- Drug
- Federal Energy Regulatory Commission
- for
- Forbes JAPAN
- Guidance
- Industry
- Notice No. 11483/TB-BNV
- Prescription
- public policy
- Regulatory
- Software
- Taiwan drug market
- United States government
- Use-Related
entities_en:
- name: Federal Energy Regulatory Commission
  type: organization
- name: Forbes JAPAN
  type: organization
- name: Notice No. 11483/TB-BNV
  type: UNKNOWN
- name: Taiwan drug market
  type: 概念
topics_en:
- public policy
- United States government
numeric_facts: []
provenance:
  doc_id: 2026-21516
  doc_id_scheme: fr_docnum
  issuer:
  - Health and Human Services Department
  - Food and Drug Administration
  doc_type: Notice
  subtype: null
  action: Notice of availability.
  significant: null
entities:
- name: Notice No. 11483/TB-BNV
  type: UNKNOWN
- name: Federal Energy Regulatory Commission
  type: organization
- name: Forbes JAPAN
  type: organization
- name: Taiwan drug market
  type: 概念
key_facts: []
related: []
related_auto:
- name: Holiday options for 2027 Lunar New Year and National Day
  type: UNKNOWN
  weight: 1.0
- name: Employers outside state administrative agencies
  type: UNKNOWN
  weight: 1.0
- name: Employers notifying staff at least 30 days before holiday arrangements
  type: UNKNOWN
  weight: 1.0
- name: Upper Peninsula Power Company
  type: organization
  weight: 1.0
- name: Brazilian Scientists
  type: organization
  weight: 1.0
computed_at: '2026-10-21T10:10:44Z'
---

# Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability

## TL;DR
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Regulatory Considerations for Prescription Drug Use-Related Software." This final guidance describes FDA's application of its drug labeling authorities to certain software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug product or a prescription drug-led, drug-device combination product that is assigned to the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research as the lead center. This guidance finalizes the draft guidance of the same title issued on September 19, 2023.

## Key Points
- (なし)

## Details
(本文なし。リンク先参照)

## Source
元記事: [Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability](https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry) — published 2026-10-21T00:00:00Z
